SyntheMed lists on Frankfurt Exchange:
This article was originally published in Clinica
Executive Summary
SyntheMed, the Iselin, New Jersey-based biomaterials company, has listed on the Frankfurt Stock Exchange in Germany. The company, which recently launched its Repel-CV surgical anti-adhesion product in Europe, said the listing is intended to increase liquidity in its stock: most of its shares are held by EU-based investors. Repel-CV is for use in cardiothoracic surgery; the company hopes to receive PMA approval for the product in the US in mid-2007.